• Nektar Therapeutics President and CEO W. Robin Howard sold 20,000 common shares on June 16-17.
• Sales priced at USD 59.97 to USD 61.65 per share.
• Direct holdings fell to 55,045 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-276236), on June 18, 2026, and is solely responsible for the information contained therein.